Open-Label Study to Assess the Effect of Long-Term Prolonged-Release Fampridine (BIIB041) on Quality of Life as Reported by Participants With Multiple Sclerosis

PHASE4CompletedINTERVENTIONAL
Enrollment

901

Participants

Timeline

Start Date

February 29, 2012

Primary Completion Date

July 31, 2013

Study Completion Date

August 31, 2013

Conditions
Multiple Sclerosis
Interventions
DRUG

Fampridine

Supplied as a 10 mg twice daily tablet and taken twice daily. Doses must be spaced at least 12 hours apart.

Trial Locations (59)

Unknown

Research Site, Concord

Research Site, Kogarah

Research Site, Liverpool

Research Site, New Lambton Heights

Research Site, Auchenflower

Research Site, Box Hill

Research Site, Clayton

Research Site, Fitzroy

Research Site, Heidelberg

Research Site, Brasschaat

Research Site, Brussels

Research Site, Diepenbeek

Research Site, Fraiture-en-Condroz

Research Site, Ghent

Research Site, Liège

Research Site, Melsbroek

Research Site, Overpelt

Research Site, Sijsele-Damme

Research Site, Wilrijk

Research Site, Copenhagen

Research Site, Nice

Research Site, Strasbourg

Research Site, Caen

Research Site, Bordeaux

Research Site, Rennes

Research Site, Nantes

Research Site, Reims

Research Site, Clemont-Ferrand

Research Site, Paris

Research Site, Amiens

Research Site, Paris

Research Site, Heidenheim

Research Site, Kassel

Research Site, Oldenburg

Research Site, Münster

Research Site, Berlin

Research Site, Erbach im Odenwald

Research Site, Hamburg

Research Site, Jena

Research Site, Osnabrück

Research Site, Schwendi

Research Site, Bari

Research Site, Florence

Research Site, Milan

Research Site, Padua

Research Site, Roma

Research Site, Eindhoven

Research Site, Hoorn

Research Site, Nijmegen

Research Site, Tilburg

Research Site, Amadora

Research Site, Coimbra

Research Site, Lisbon

Research Site, Porto

Research Site, Salford

Research Site, Nottingham

Research Site, Glasgow

Research Site, Liverpool

Research Site, London

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Biogen

INDUSTRY